Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03206814
Other study ID # 09A721
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 11, 2021
Est. completion date December 2024

Study information

Verified date August 2023
Source Istituto Auxologico Italiano
Contact Gianfranco Parati, MD
Phone +390261911
Email gianfranco.parati@unimib.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.


Description:

CHARGE-APP is a proof-of-concept one-year prospective, randomized, open-label, blinded endpoint study (PROBE) including 2 groups of patients randomized to different treatment strategies: 1. a new management strategy, named POST (i.e. "Patient Optimal Strategy for Treatment"), consisting in providing the patients with a system to communicate home blood pressure measurements to a referral centre, and the referral centre with an online platform to organize and easily interpret the information sent by patients and to monitor the patients' status; 2. usual care, consisting in regular visits at the referral centre. Patients will be enrolled over 3 months and will be randomly allocated to one of the study groups. Follow-up phase will last 12 months after randomization and will focus on changes in ambulatory systolic BP (primary endpoint), in diastolic ambulatory BP, in office SBP and DBP, in Home SBP and DBP, in left ventricular mass index (LVMI) and urinary albumin excretion (UAE), all secondary end-points. All patients will perform visits at baseline, three, six and twelve months. Physical examination, history of the patient and clinical blood pressure values will be obtained at every visit. Echocardiogram, ECG, urine samples (UAE, urinary albumin/creatinine and 24-h ambulatory blood pressure monitoring (ABPM) will be performed at baseline, three months, six months and study end. Blood samples (full blood count, creatinine, Na+, K+, fasting glucose, HbA1c, uric acid, lipids) will be performed at baseline; another blood sample will be collected at twelve months for measurement of serum creatinine (and renal function). UAE will be measured at baseline and study end, on morning urine samples. Patients randomized to POST-strategy will measure Home BP two days a week (two measurements in the morning and two measurements in the evening) and communicate these values with the ESH CARE app; furthermore, before each visit they will measure their Home BP for 7 consecutive days (two measurements in the morning and two measurements in the evening), according to current guidelines on hypertension. Patients randomized to usual care will also measure Home BP for 7 consecutive days at baseline and at study end, to provide a comparison. Operators (i.e. investigators dedicated to the follow-up of POST-strategy) will check these data organized by the POST system at least every 15 days, and adjust pharmacological therapy, if needed. In patients randomized to usual care, therapy will be adjusted only at follow-up visits (i.e. at three and six months). Pharmacological therapy will be increased or decreased according to blood pressure values; investigators may follow a therapy algorithm based on ESH/ESC guidelines, but are free to individualize it.


Recruitment information / eligibility

Status Recruiting
Enrollment 480
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Male and female subjects; - Age 18-80 years; - Either the patient or another person close to him/her should possess a smartphone compatible with the ESH CARE app and be capable of using it; - Uncontrolled (untreated or treated) hypertension, defined as office BP =140/90 mmHg, and Ambulatory 24h ABP =130/80 mmHg Exclusion Criteria: - eGFR <45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009); - Severe uncontrolled hypertension (i.e. BP =200/120 mmHg despite treatment); - Known secondary hypertension; - Orthostatic hypotension (SBP fall > 20 mmHg on standing); - Unstable clinical conditions or severe disease with short life expectation; - Known atrial fibrillation; - Hepatic disease as determined by either AST or ALT values > 2 times the upper limit of normal; - History of gastrointestinal surgery or disorders which could interfere with drug absorption - History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years; - History of clinically significant autoimmune disorders such as systemic lupus erythematosus; - History of drug or alcohol abuse within the last 5 years; - History of non-compliance to medical regimens and/or patients who are considered potentially unreliable; - Dementia (clinical diagnosis); - Inability or unwillingness to give free informed consent; - Inability to use even simple communication technologies; - Pregnancy or planned pregnancy during study period

Study Design


Intervention

Other:
Usual care
Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
POST-strategy
Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.

Locations

Country Name City State
Argentina Spanish Hospital of Mendoza Mendoza
China Shanghai Institute of Hypertension Shanghai Huangpu

Sponsors (1)

Lead Sponsor Collaborator
Istituto Auxologico Italiano

Countries where clinical trial is conducted

Argentina,  China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ambulatory Systolic Blood Pressure Change in ambulatory 24h systolic blood pressure 12 months
Secondary Ambulatory Diastolic Blood Pressure Change in ambulatory 24h diastolic blood pressure 12 months
Secondary Difference between Office Blood Pressure and Home Blood Pressure Differences between office blood pressure and home blood pressure (both systolic and diastolic) 12 months
Secondary Left ventricular mass index Change in left ventricular mass index by ecocradiographic evaluation 12 months
Secondary Left ventricular hypertrophy Change in ECG indices of left ventricular hypertrophy 12 months
Secondary Urinary albumin to creatinine ratio Change in urinary albumin to creatinine ratio 12 months
Secondary Estimated glomerular filtration rate Change in estimated glomerular filtration rate 12 months
Secondary Normalization rate of blood pressure Normalization rate of BP by all the measuring devices: office BP, HOME BP and ABPM 12 months
Secondary ABPM variables Change in a number of variables derived from ABPM (day-time SBP/DBP, Night-time SBP/DBP, nocturnal dipping of SBP/DBP, morning surge of SBP/DBP, BPV (daytime and night-time SBP/SBP SD, CV; 24h SBP/DBP ARV, 24h SBP/DBP wSD, AASI) 12 months
Secondary Prescribed antihypertensive drugs Number of prescribed antihypertensive drugs 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05086523 - Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study Phase 1/Phase 2
Active, not recruiting NCT03503773 - The TARGET BP OFF-MED Trial Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Recruiting NCT06019598 - Licorice and Home Blood Pressure, Additional Study N/A
Completed NCT04495231 - Sympathetic Activity and Cardiometabolic Complications
Completed NCT04119999 - A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling N/A
Recruiting NCT04505618 - Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease N/A
Recruiting NCT04863508 - Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.
Completed NCT05185297 - Recreational Futsal for Controlled Hypertension N/A
Completed NCT03855605 - Diagnosis of Hypertension by Home Blood Pressure Monitoring
Completed NCT03901183 - Plant-based Nutrition for Patients With Cardiovascular Risk Factors N/A
Recruiting NCT06348576 - Phase III Study to Evaluate the Efficacy and Safety of AD-209 Phase 3
Recruiting NCT06343246 - Functional Inspiratory Muscle Training in Patients Diagnosed With Hypertension N/A
Completed NCT06359873 - Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
Recruiting NCT04565548 - Hypertension Treatment Adherence Improving Trial N/A
Recruiting NCT06205628 - Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension Phase 1
Recruiting NCT04613193 - Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis N/A
Completed NCT03841383 - Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk